Urologie pro praxi 5/2017
Does the standard practice confirm the efficacy of vinflunine in the treatment of metastatic urothelial carcinoma?
Vinflunine has been approved in Europe for second-line treatment of metastatic and advanced urothelial cancer after failure of platin-containing therapy. The reports from daily clinical practice with more heterogeneous patient populations present valuable sources of information on treatment modalities, risk stratification and side-effect management in this narrow indication. They confirm the results from pivotal trials with regard to safety and efficacy.
Keywords: metastatic and advanced urothelial cancer after failure of platin-containing therapy, vinflunine, second line treatment.
